Loading organizations...
§ Private Profile · Zug, Zug, Switzerland
biopharmaceutical company developing novel therapies for cardiovascular diseases, focused on Ularitide for ADHF.
Cardiorentis is a biopharmaceutical company based in Zug, Switzerland, that develops novel therapies and protein biology-based treatments for cardiovascular diseases and heart failure. The organization utilizes a disease-based technology platform to design small molecule compounds and peptides targeting unmet medical needs in the cardiovascular sector. Its lead product candidate, Ularitide, is an investigational treatment for acute decompensated heart failure that underwent the TRUE-AHF Phase III clinical trial under the direction of international principal investigator Milton Packer. To support regulatory submissions and the commercial build-out of this therapy, the privately held enterprise raised CHF 60 million in Series B financing in 2016, following a previously announced €45 million funding round. Operating since at least 2010, Cardiorentis was founded by Johannes Holzmeister, who served as chief executive officer before later leading the spin-out company DiNAQOR.
Cardiorentis has raised $117.8M across 2 funding rounds.
Cardiorentis has raised $117.8M in total across 2 funding rounds.
Cardiorentis has raised $117.8M across 2 funding rounds. Most recently, it raised $60.0M Series B in January 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 11, 2016 | $60M Series B | — | — | Announced |
| Sep 19, 2014 | $57.8M Venture Round | Healthcare Royalty Partners | — | Announced |
Cardiorentis has raised $117.8M in total across 2 funding rounds.
Cardiorentis's investors include HealthCare Royalty Partners.